Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
AstraZeneca discontinues development of Galida (tesaglitazar)
June 2nd, 2006
AstraZeneca announced the discontinuation of the Galida development program. Galida is a dual PPAR alpha and gamma agonist and was in phase III development for the treatment of the glucose and lipid abnormalities associated with type 2 diabetes. Following analysis and interpretation of recently obtained results from the first four of eight phase III clinical trials (GALLANT 6,7,8 and 9) and one phase II trial (ARMOR), which were reviewed in consultation with external experts, the company considers that the overall benefit/risk profile is unlikely to offer patients significant advantage over currently available therapy. Central to...
Source: Medicine & Law Weekly (2006-06-02)
|
